Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Takeda pharmaceutical company limited save search
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Plasma Therapy Global Market Report 2024 - Projected Compound Annual Growth Rate of 12.5%, with Market Set to Reach $0.88 Billion in 2028
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -0.38%
H: 0.14%
C: -0.14%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 2.0%
H: 2.28%
C: 1.63%
ADMA 4 | $6.27 1.13% 1.12% 3.4M
|
Health Technology
|
| O: 0.19%
H: 2.5%
C: 1.35%
report reach global set therapy growth market
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.38%
H: 0.78%
C: 0.78%
hyqvia approved therapy
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.61%
C: -0.2%
ohb-607 license group oak agreement therapy
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.64%
H: 0.21%
C: -1.79%
hyqvia chmp positive therapy
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2023-09-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.63%
H: 0.5%
C: 0.31%
entyvio fda disease active therapy
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
Published: 2023-07-20 (Crawled : 00:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.65%
H: 0.49%
C: 0.07%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.35%
H: 2.21%
C: 1.9%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -0.33%
H: 2.55%
C: 1.4%
treatment designation china therapy study
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Published: 2023-06-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.25%
H: 0.31%
C: -0.12%
hyqvia meeting set trial therapy
Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
Published: 2023-05-15 (Crawled : 17:00) - prnewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.24%
H: 0.66%
C: 0.66%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.61%
H: 0.3%
C: 0.24%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.2%
H: 0.13%
C: -0.22%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.27%
H: 0.6%
C: 0.41%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.38%
H: 0.91%
C: 0.69%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.14%
H: 0.28%
C: 0.11%
report cancer global therapy growth market
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Published: 2023-04-27 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.36%
C: 0.3%
entyvio fda active resubmission therapy
Stem Cell Therapy Global Market Report 2022: Advancements in Stem Cell Clinical Trials Fuels Growth
Published: 2023-04-05 (Crawled : 23:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.24%
H: 2.42%
C: 1.94%
report cell trials global therapy growth market
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
Published: 2023-02-22 (Crawled : 22:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.32%
H: 0.44%
C: 0.0%
CDXS | $2.815 0.54% 0.53% 470K
|
Process Industries
|
| O: 1.09%
H: 0.09%
C: -1.26%
therapy
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
Published: 2023-01-11 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.04%
H: 0.32%
C: 0.19%
exkivity approval therapy
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Published: 2022-10-20 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.6%
H: 0.6%
C: 0.04%
pharma disease collaboration agreement therapy
The Worldwide Enzyme Replacement Therapy Industry is Expected to Reach $15 Billion by 2028
Published: 2022-09-16 (Crawled : 14:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.15%
H: 1.04%
C: 0.15%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.62%
H: 1.01%
C: 0.46%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.95%
H: 1.21%
C: 1.1%
FOLD F | $10.62 2.81% 2.73% 2.5M
|
Health Technology
|
| O: -0.91%
H: 0.18%
C: -2.12%
expected therapy
Global Cell Therapy Manufacturing Market to Reach $6.01 Billion by 2026
Published: 2022-09-13 (Crawled : 11:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -1.17%
H: 0.15%
C: -1.47%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.72%
H: 0.07%
C: -1.27%
CTLT | $55.48 -0.57% -0.4% 1.6M
|
Health Technology
|
| O: -2.7%
H: 0.52%
C: -1.7%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: -3.41%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.25%
H: 0.05%
C: -4.29%
global therapy market
Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials
Published: 2022-09-01 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.58%
C: 0.29%
isp-001 fda clearance trials application therapy mps-ih mps-i
Autologous Cell Therapy Market to Reach Value of US$ 34.7 Bn by 2027, States TMR Report
Published: 2022-08-15 (Crawled : 12:00) - prnewswire.com
USRM | $0.0001 1300.0% 290K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -3.28%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.63%
H: 0.85%
C: 0.56%
VCEL | $43.74 -0.27% -0.27% 520K
|
Health Technology
|
| O: -1.03%
H: 9.88%
C: 9.66%
LCTX | $1.15 -4.17% 0.0% 1.1M
|
Health Technology
|
| O: -0.64%
H: 2.88%
C: 1.92%
report therapy market
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
Published: 2021-10-27 (Crawled : 20:00) - fda.gov
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.44%
H: 2.01%
C: 0.82%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.03%
H: 3.33%
C: 0.07%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.91%
H: 2.93%
C: 2.79%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.19%
H: 2.32%
C: 1.7%
disease fda gene therapies therapy gene therapy rare
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.